Pharmx Technologies Limited · ASX:PHX
Pharmx Technologies — H1 FY2024 Earnings Presentation
24 slides from Pharmx Technologies's earnings presentation, Feb 23, 2024
Slide 1: Market Release: PharmX Results for Half-Year Ended 31 December 2023
PharmX Technologies Limited ABN 25 000 091 305 Level 11, 17 Castlereagh Street, Sydney NSW 2000 www.pharmx.com.au Market Release 23 February 2024 PharmX Results for the half-year ended 31 December 2023 PharmX Technologies Limited (ASX: PHX) is pleased to announce its interim results for the half-yea
Slide 2: About PharmX Technologies
Commenting on the results, PharmX Technologies CEO, Thomas Culver said: “I’m delighted to join PharmX Technologies at such an exciting time in the Company’s evolution. The sale of the pharmacy software business in September enables us to further cement our strategic position as a critical provider o
Slide 3: PharmX Technologies Limited Investor Presentation
PharmX Technologies Limited Investor Presentation CEO Tom Culver & Interim CFO Jon Newbery 23 February 2024 This presentation has been authorised for lodgment by the Board
Slide 4: Important Notice & Disclaimer
Important Notice & Disclaimer This presentation has been prepared by PharmX Technologies Limited (PHX assurance that the results, performance or achievements expressed or or the Company or PharmX). It should not be considered as an offer or implied by the forward-looking statements contained in this
Slide 5: Presenters
Presenters Thomas Culver Jon Newberry Chief Executive Officer Non-Executive Director (interim CFO) • 20y experience in CEO and Snr Exec • 30y experience in Snr Exec and Board for Private and ASX listed Co. roles for ASX listed Co. • Previously Chief Operating Officer of • Chairman of Repurpose It Pt
Slide 6: PharmX Technologies Overview
PharmX Technologies Overview FY24 • Well capitalized and • 1H FY 24 streamlined focus positioned as a strong • Legacy Corum Group (+25ys on technology orientated platform for growth in operation) business: PHX, PHXC, MDS Focused and ambitious • Disposal of the eCommerce • • Focused revenue models gr
Slide 7: PharmX Technologies Limited
PharmX Technologies Limited Critical EDI infrastructure to the industry supply chain of retail , Purpose-built marketplace for pharmacists and suppliers pharmaceutical and NDSS goods Est. Est. 2006 2022 Primary customer: Primary customer: Supplier Pharmacy / Supplier Service: Service: Integrated EDI
Slide 8: Key Updates H1 FY24
Key Updates H1 FY24 PharmX PharmXchange Master Data Services Staffing Continued focus on EDI Development support brought Rollout of phase 1 Data Thomas Culver appointed as solutions. Supporting Gateways in-house Solution –(industry product the new PharmX Technologies 2 – 3 with development f
Slide 9: Key Financial Updates H1 FY24
Key Financial Updates H1 FY24 Operating results Capital Return Court Case Revenue growth of 5%, while The disposal of the pharmacy Judgement handed down in delivering a strong EBITDA software business was 2023 by the Victorian Supreme margin of 33%. completed in September 2023. Court ordering
Slide 10: New Focused Team Structure
New Focused Team Structure Thomas Culver CEO Finance/Operations Commercial/Sales Product/Technology Marketing/Brand Data Services Chief Financial Officer GM Commercial Enterprise Architect Head of Brand and Marketing Head of Data Senior Accountant Partnership Manager Head of PharmXchange SDR x 5 As
Slide 11: PharmX EDI Developments
PharmX EDI Developments Gateway 4 Master Date Solutions Service Gateway 4 Orders - Traditional EDI Invoices - (Gateway 1 – 3) Advanced Shipping Notices - Account Management - Enhanced EDI (Gateway 3) Supplier Inventory - Retail Sales - Master Data Platform PharmX and PharmXchange system connectivity
Slide 12: PharmXchange Overview
PharmXchange Overview +240 Brands 11k highly discoverable Multi item checkout, Near term focus with platform exclusive to increase activation products, with supplier sponsorship W/S stock / payments info promotions and engagement AI driven experience (trending, recommender system) Order automation P
Slide 13: Profit and Loss H1 FY24
Profit and Loss H1 FY24 Revenue growth of 5%, while delivering a strong EBITDA margin of 33% $’000 H1 FY24 H1 FY23 Var $ Var % Revenue 3,235 3,082 153 5% • Underlying results exclude the pharmacy software business and non-recurring costs Underlying costs (2,155) (2,362) 207 (9)% • Revenue growth mai
Slide 14: Loss from discontinued operations
Loss from discontinued operations Loss from discontinued operations includes the loss on disposal and the results from operations until disposal $’000 H1 FY24 Proceeds on disposal 6,250 • The sale of the pharmacy software business to Jonas Net tangible asset deficiency to be paid Software AUS Pty Lt
Slide 15: Cashflow for H1 FY24
Cashflow for H1 FY24 Continuing Positive Operating Cashflow $'000 H1 FY24 H1 FY23 Var $ Var % Receipts from customers - continuing 3,298 3,243 55 2% operations Statutory Operating Cashflow 1,936 1,700 236 14% • Underlying operating cashflow was positive both Add-Back Non-recurring PharmX 66 1,059 (9
Slide 16: Closing Summary
Closing Summary A positive result for 1HFY24, with opportunities for growth • Independent service provider to the pharmacy market with focused business model and product solutions • Long term opportunities for product optimization and service expansion to increase market dominance • Focused structur
Slide 17: Questions
Questions
Slide 18: Thank You
Thank You Contact: [email protected]
Slide 19: Appendix
Appendix
Slide 20: Corporate Overview
Corporate Overview PharmX Technologies Limited (ASX:PHX) at Capital Structure 19 February 2024 Share Price 2.7cps Shares on Issue (m) 598.5 Market Capitalisation $16.2m Options / Perf Rights (m) 11.9 Enterprise Value (Cash 31/12/24) $3.8m Diluted Issued Capital (m) 610.4 On 22 November 2023, PharmX
Slide 21: Profit & Loss
Profit & Loss Profit & Loss ($'000) H1'24 H1'23 ∆ PCP Revenue from continuing operations $3,235 $3,082 5% Cost of sales ($610) ($614) (1)% Employee benefits ($1,022) ($1,186) (14)% Marketing ($65) ($84) (23)% Technology, communication and cloud costs ($201) ($174) 16% Legal ($70) ($1,123) (94)% Prof
Slide 22: Cashflow
Cashflow Cash flow ($'000) H1 FY24 H1 FY23 Cash flows from operating activities Receipts from customers 4,683 6,587 Payments to suppliers and employees (4,503) (6,474) Interest and other revenue received 93 37 Research and development incentive received, net of income tax paid 1,663 1,550 Net cash f
Slide 23: Balance Sheet
Balance Sheet 31 December 24 - H1 Balance Sheet ($'000) 30 June 23 - H2 FY23 FY24 Current assets Cash and cash equivalents $12,440 $12,806 Trade and other receivables $2,652 $946 Income tax receivable $498 $1,659 Other assets $222 $229 Assets classified as held for sale - $6,949 Total $15,812 $22,58
Slide 24: Share Registry
Share Registry Top shareholders at 19 February 2024 Rank Name Units % Units 1 LUJETA PTY LTD <MARGARET A/C> 89,480,946 14.95% 2 ARROTEX INVESTMENTS HOLDING 1 PTY LTD 60,000,000 10.02% 3 NATIONAL NOMINEES LIMITED 40,242,512 6.72% 4 MERSAULT PTY LTD<ENGLAND S/F A/C> 26,766,667 4.47% 5 MR DAVID GERALD
PharmX Technologies — H1 FY2024 Earnings Presentation on 6ix